Allergan plc. (AGN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Allergan plc. stock price, AGN
Allergan plc. stock chart:
Allergan plc. close price: 237.33
Stock price forecast:
DOWN TO -6.19%
Total forecasts: 89
Reached: 31 (34.83%)
Total Win: 213.67 (100.09%)
Showing 1-10 of 520 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Allergan plc. latest news:
BRIEF-Allergan says Goldman Sachs Group reported 6.3 pct passive stake in co as of Dec. 31 - SEC filing
* The Goldman Sachs Group Inc reports 6.3 percent passive
stake in Allergan Plc as of dec. 31, 2016 - sec filing
Source text: (http://bit.ly/2knWz9s)
Further company coverage:
Elliott Management picks up new stakes in Alcoa, Dell Technologies
Paul Singer's Elliott Management disclosed new stakes in Dell Technologies, and Alcoa Corp. in the fourth quarter, according to a Tuesday regulatory filing. Between the third and fourth quarters, Singer's fund acquired 7.1 million shares of Dell worth $392 million. That paired with the purchase of Dell call options, which confer an owner the right but not the obligation to buy shares at a set price, representing 2.8 million shares or $154 million, according to file-tracking firm WhaleWisdom.com. The fund picked up 10.2 million shares of Alcoa worth $287 million, and 3 million shares of Cognizant Technology Solutions Corp. valued at $168 million, as of Dec. 31. Meanwhile, Elliott reduced call options tied to biopharmaceutical company Allergan , cutting those holdings by the equivalent of 1.1 million shares, or $210 million, as of Dec. 31. It made no change to its direct exposure to Allergan's stock, retaining a 2.7 million shares worth about $574 million. Large investors are required to reveal their long equity holdings at the end of each quarter in public filings.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Appaloosa Management snaps up Allergan shares in 4th quarter
Billionaire hedge-fund investor David Tepper's Appaloosa Management was a big buyer of biopharmaceutical firm Allergan PLC in the fourth quarter, according to a Tuesday regulatory filing. Between the end of the third and fourth quarter, Appaloosa boosted its stake in Allergan by more than 3.043 million shares, or 249%, to a total of more than 4.261 million shares, according to filings-tracker Whalewisdom.com, making Allergan the fund's top holding. Appaloosa also reduced its holdings of put options on the SPDR S&P 500 ETF , which give the holder the right but not the obligation to sell the underlying security at a set price. In other moves, Appaloosa bought shares of Teva Pharmaceutical and PNC Financial Services , while selling its stake of 4.165 million shares of Synchrony Financial . Large investors are required to reveal their long equity holdings at the end of each quarter in filings with the Securities and Exchange Commission.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq
Shares of Zeltiq Aesthetics (ZLTQ) got off to a hot start this week, rallying about 13% Monday after it was announced Allergan (AGN) would acquire the company for $2.47 billion, or about $56.50 per share. Allergan (AGN) shares added about 1%, to $248.86. Zeltiq is another company aimed at keeping people looking younger, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Da...
Allergan to acquire body contouring company Zeltiq Aesthetics for $2.5 billion
Allergan said early Monday it will acquire body-contouring company Zeltiq Aesthetics for $2.475 billion, with the deal expected to close in the second half of this year. Zeltiq Aesthetics has a cooling technology that has been approved for fat reduction, which Allergan said was a $4 billion market opportunity worldwide and growing. Allergan announced in December it would acquire Acelity's LifeCell, which produces various products used for breast reconstruction and soft tissue repair, and its aesthetics business -- including Botox, line fillers, implants and eye care -- is expected to drive much of the company's growth in the coming years. Allergan is creating a "world-class aesthetics business," Chief Executive Brent Saunders said. "With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices," he said.
Zeltiq Aesthetics shares, which were halted before the announcement, have surged 25.4% over the last three months. Allergan shares have surged 18.7% over the last three months, compared with a 7.0% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Dan Loeb took new stakes in J.P. Morgan, B. of A. and dumped Allergan
Billionaire hedge fund manager Dan Loeb's Third Point LLC took new positions in banking giants J.P. Morgan Chase and Bank of America in the fourth quarter, while dumping his stake in biopharmaceutical company Allergan, according to a regulatory filing on Friday. Among other moves, Third Point held 17.5 million shares of Bank of America as of Dec. 31, according to filings tracker Whalewisdom.com. Other new stakes included 5.25 million shares of J.P. Morgan Chase. The firm sold its entire stake of 3.785 million shares of Allergan . Large investors must disclose the long stock positions they held at the end of each quarter.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Allergan's stock rallies after adjusted profit and sales beat expectations
Shares of Allergan PLC (AGN) surged 1.8% in premarket trade Wednesday, after the biopharmaceutical company reported fourth-quarter adjusted profit and sales that beat expectations. For the quarter to Dec. 31, the net loss was $70.2 million, or 20 cents a share, compared with a loss of $700.5 million, or $1.78 a share, in the same period a year ago. Excluding non-recurring items, such as research and development-related charges and impairment, adjusted earnings per share came to $3.90,...
Allergan says the FDA has approved its cream for facial redness
Allergan PLC said early Thursday that the Food and Drug Administration has approved its cream for persistent facial redness in adults. An estimated 16 million Americans have rosacea, which most commonly manifests as persistent facial redness and can be triggered by sun exposure, stress, exercise and more. The treatment, Rhofade, will be available commercially starting in May, Allergan said. Allergan shares, which were up a scant 1.0% in pre-market trade, have dropped 5.4% over the last three months, compared with a 6.0% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 1-Allergan to pay $15 mln over failing to disclose merger talks
WASHINGTON, Jan 17 (Reuters) - A unit of Botox maker
Allergan Plc will pay a $15 million penalty and admit to
wrongdoing, after U.S. regulators on Tuesday accused the unit of
failing to disclose 2014 merger talks with Actavis, the U.S.
Securities and Exchange Commission said.
Allergan to pay $15 million over failing to disclose merger talks
Botox maker Allergan plc (AGN) will pay a $15 million penalty and admit to wrongdoing, after U.S. regulators on Tuesday accused the company of failing to disclose merger talks with Actavis, the U.S. Securities and Exchange Commission said.
Alliance California Municipal Income Fund IncAKP
Alliance Data Systems CorporationADS
Alliance National Municipal Income Fund IncAFB
Alliance One InternationalAOI
Alliance World Dollar Government Fund IIAWF
ALLIANCEBERNSTEIN INCOME FUND INCACG
Allianceberstein Holding L.P.AB
Alliant Energy CorporationLNT